Oxaliplatin for melanoma – pro
Oxaliplatin is a platinum derivative without nephrotoxicity with in vitro activity against human melanoma cell lines. A Phase I and II trials suggested activity in melanoma, although a combination of oxaliplatin, docetaxel, and GM-CSF had limited clinical activity in previously treated patients with advanced melanoma. A non-nephrotoxic platinum compound active in melanoma is of interest in the development of combination chemo-or chemoimmunotherapy. This trial is an attempt to begin doing this in a pahse I trial setting, that is, with dose escalation of oxaliplatin.
The proposed study is: A Phase I Study of Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic Fluorouracil, Leucovorin and Avastin for Patients with Advanced Solid Tumors Metastatic to the Liver. The goal of this clinical research study is to find the highest tolerable dose of oxaliplatin used in combination with 5-fluorouracil, leucovorin, and Avastin® (bevacizumab) for patients with advanced cancer that has spread to the liver. The safety and effectiveness of this study drug combination will also be studied. This si celarly experiemntal by any definition.
Oxaliplatin is a platinum derivative without nephrotoxicity with in vitro activity against human melanoma cell lines. A Phase I and II trials suggested activity in melanoma, although a combination of oxaliplatin, docetaxel, and GM-CSF had limited clinical activity in previously treated patients with advanced melanoma. A non-nephrotoxic platinum compound active in melanoma is of interest in the development of combination chemo-or chemoimmunotherapy. This trial is an attempt to begin doing this in a pahse I trial setting, that is, with dose escalation of oxaliplatin.
The proposed study is: A Phase I Study of Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic Fluorouracil, Leucovorin and Avastin for Patients with Advanced Solid Tumors Metastatic to the Liver. The goal of this clinical research study is to find the highest tolerable dose of oxaliplatin used in combination with 5-fluorouracil, leucovorin, and Avastin® (bevacizumab) for patients with advanced cancer that has spread to the liver. The safety and effectiveness of this study drug combination will also be studied. This is clearly experimental by any definition.